Board documents

7 December 2016

00a Document list pdf

Board -201 6-Mtg -2-Doc 00 a



G avi Alliance Board Meeting
7-8 December 2016
Sofitel Abidjan Hotel Ivoire, Abidjan, C ?te d?Ivoire

Monday 5 and Tuesday 6 December : Pre -Board meetings & Field Visits
Wednesday 7 December : 08.45 -18.15 (Board meeting Day One)
Thursday 8 December : 0 9.0 0-16.30 (Board meeting Day Two)
Quorum: 14

Document list

No. Document
00a Document list
00b Agenda
01a Declarations of interest
01b Minutes from 22 -23 June 2016
01c Action Sheet
01 d Workplan including 2017 Board meeting dates
02a Consent agenda : Board/Committee member appointments (To follow)
02b Consent agenda: IRC nominations (To follow)
02c Consent agenda: Changes to Committee Charters (To follow)
02d Consent agenda: Board Travel Policy review (To follow)
02e Consent agenda: Programme fun ding policy update
02f Consent agenda: Programme funding request
02g Consent agenda: Co -financing waiver
02h Consent agenda: Country engagement framework
03 2016 -2020 Strategy: Implementation and progress
04 CEO?s report (To follow)
05 Financial fore cast and programme funding envelopes
06 Partners? Engagement Framework
07 Country Presentation ? C?te d?Ivoire ? No paper
07a Country Programmes: strategic issues
07b Country Programmes: Cold Chain Equipment Optimisation Platform (CCEOP)
08 a Fragile s ettings , emergencies and displaced people
08b Potential Gavi support for immunisation in Syria
09 Chair?s reflections on the day ? No paper

7 December 2016

00b Agenda pdf

Board -2016 -Mtg -2-Doc 00b




G avi Alliance Board Meeting
7-8 December 2016
Sofitel Abidjan Hotel Iv oire , Abidjan , C ?te d?Iv oire

Monday 5 and Tuesday 6 December : Pre -Board meetings & Field Visits
Wednesday 7 December : 08.45 -18. 15 (Board meeting Day One)
Thursday 8 December : 0 9.0 0-16.30 (Board meeting Day Two)
Quorum: 14


Agenda


Pre -Board Meetings ? Monday, 5 December 2016
Item Subject Room Schedule

? All Chairs meeting Daloa 09.00 -11.00
? Governance Committee meeting Daoukro 11.15 -14.15
? Audit and Finance Committee meeting Odienne 14.30 -16.30
? Developing Countries Board members meeting Salle des F ?tes 15.30 -17.30
? Technical Briefing Session ? Finance Salle des F ?tes 18.00 -19.00
? Unaffiliated Board members meeting Daloa 19.15 -20.15
? Gavi Donors? meeting Daoukro 19.30 -21.30


Field Visits & Pre -Board Meetings ? Tuesday , 6 December 2016
Item Subject Room Schedule

? Field Visits 08.00 -14.30
? Board Meeting: Closed session for Board members and
Alternate Board members
Salle des F ?tes 15.00-20 .30

7 December 2016

01a Declarations of interest pdf

Board -201 6-Mtg -2-Doc 01 a



Gavi Alliance Board Meeting
7-8 December 2016
Sofitel Abidjan Hotel Ivoire, Abidjan, C ?te d?Ivoire

Quorum: 14
Declarations of Interest

Declarations
Section 5.2 of the Conflict of Interest Policy states, ?Annually, each member of the Board
(including alternate Board members and Committee delegates)...shall complete and submit a
conflict of interest form to be distributed by the Managing Director, Law and Governance.? The
following declarations were made by members of the Board on their most recent annual
statements:
Board members:
Member Org anisational Interest s Financial/Personal/Advisor Int
Ngozi Okonjo -Iweala , Chair None Gavi -appointed special adviser
Flavia Bustreo, Vice Chair WHO Gavi -appointed special adviser
Gunilla Carlsson None None
Yifei Li None Man Group (Country Chair)
Rockefeller Foundation (Board)
Helen Rees None None
William H. Roedy None None
Richard Sezibera None Gavi -appointed special adviser
David Sidwell None
Chubb Limited (Board)
UBS (Board, Risk and
Governance C ommittees)
Stephen Zinser None None
Orin Levine Bill & Melinda Gates Foundation PATH (Family)
Tim Evans The World Bank None
Bahar Idriss Abug arda Government of Sudan Gavi -appointed special adviser
Edna Yolani Batres Government of Honduras Gavi -appoint ed special adviser
Raymonde Goudou Coffie Government of C?te d?Ivoire Gavi -appointed special adviser
Ingrid -Gabriela Hoven GER (GER/FRA/LUX /EC/ IRL ) None
Angela Santoni IT (CAN/IT/ SP) None
Eivind Homme NOR ( NOR /NE D/SWE) None
Donal Brown UK ( UK/Qatar) None
Irene Koek USA ( USA/ AUS/JPN/KOR) None

7 December 2016

01b Minutes from 22 23 June 2016 pdf

Board -2016 -Mtg -01 1
Minutes


Gavi Alliance Board Meeting
22-23 June 2016
Starling Hotel, Geneva, Switzerland


1. Chair?s report

1.1 Finding a quorum of members present, the meeting commenced at 08.40 Geneva
time on 22 June 201 6. Ngozi Okonjo -Iweala , Board Chair , chaired the meeting .

1.2 The Chair welcomed new Board member s and Alternate Board member s, as well
as Ren? Karsenti, Chair of the International Finance Facility for Immunisation
(IFFIm) , other directors of t he IFFIm Board and Rob Moodie, Chair of the
Evaluation Advisory Committee . The Chair noted that departing members would
be recognised for their service at the dinner that evening.

1.3 The Chair discussed changes to the presentation of the Board pack in order to
reduce the volume and technical density of the m aterials provided to Board
member s in preparation for the meeting and invited Board members to continue to
provide feedback on this in order to ensure continuous improvement. She also
indicated that as Chair her wish is for less formality, more exchange and dialogue
between Board members at the meetings .

1.4 The Board met in executive session on the evening of 21 June and again on 23
June to discuss a number of items including the Board an d Committee self -
evaluation process and to review the CEO performance appraisal process.

1.5 In relation to the self -evaluation process, the Chair highlighted th e opportunity that
this provides, not only for her as new Board Chair but also for the Board, to a ddress
any issues which could improve Board performance. The ultimate aim is to
improve the efficiency and effectiveness of the Board to ensure that it is fit for
purpose to deliver on the new strategy.

1.6 Standing declarations of interest were tabled to the Board (Doc 01a in the Board
pack). The Chair thanked Board Members and Alternate Board members for
responding promptly to the Secretariat?s r equest for their updated Conflicts of
Interest Declarations this year and highlighted that this is an important pa rt of the
Board?s integrity efforts and governance. The Chair noted that in the context of the
items for decision on the agenda , there were a number of Board member s who
would have conflicts of interest and that these would be raised at the appropriate
time and recorded in the applicable parts of the minutes.

1.7 The Board noted its minutes from 2-3 December 201 5 (Doc 01b), which were
approved by no objection on 12 April 201 6. The Board also noted its workplan
(Doc 01c) and the Chair encouraged Board members to contribute to the forward
plan by raising issues which they may wish to add either with her directly or with
the Secretariat .
------

7 December 2016

01c Action Sheet pdf





G avi Alliance Board

Action sheet as of 23 November 2016

Request Matter Responsible Action taken
22 -23 June
2016
? 4
CEO?s report :
? Request for a pre -Board technical
briefing session on CSO?s role in
contributing to coverage and
equity

Secretariat
(Armstrong )

Provisionally
planned for
June 2017
22 -23 June
2016
? 4
CEO?s report:
? Ensure that risk is a standing item
on the agenda for all Board
meetings going forward

Secretariat
(Armstrong)
Included as a
standing item
on Board
workplan

22 -23 June
2016
? 8
Report from Audit and
Investigations :
? Explore if work can be done with
countries to prevent misuse

Secretariat
(Lamb )

Extended
analysis and
reported to AFC
on key themes
from
programme
audits. Agreed
to review with
Country
Programme s to
prioritise, and to
identify
mitigating
actions. Report
to AFC on
progress

22 -23 June
2016
? 13
Partners? Engagement Framework
& Alliance Accountability
Framework:
? Comparison of new business model
with the previous model

Secretariat
(Gupta/De
Chaise martin )

Will be
addressed as
part of the
prospective
evaluation of
Technical
Assistance (TA)


7 December 2016

01d Workplan including 2017 Board meeting dates pdf

BOARD WORK PLAN
Graphical format


GAVI Alliance Board Agendas
FOR BOARD DECISION/INFORMATION/GUIDANCE
Board Chair or Vice Chair appointment (Consent Agenda)
Board/Cte member appointments (Consent Agenda)
Cte chair appointments (Consent Agenda)
Statutes and By-law changes (Consent Agenda)
Changes to Committee Charters (Consent Agenda)
Review of risk appetite statement (Consent Agenda)
Partners' Engagement Framework
Country Engagement Framework
Review of fragility and immunisation policy
Review of Cold Chain Equipment Optimisation Platform (CCEOP)
Financial update and programme funding envelopes
Gavi's engagement in IPV post 2018
Leadership, management and coordination
Annual financial report
Chair rpt (Decl of Int, Mins, Acts, W kpl)
CEO report
2016-2020 Strategy: Implementation and progress
Committee chair reports
IFFIm report
Country Programmes: strategic issues
Risk management update
Review of decisions and actions
Any other business
Financial update
Report from Audit and Investigations
Decision
Decision
Decision
Decision
Decision
Decision
Decision
Discussion
Decision
Information
Information
Information
Discussion
Discussion
Information
Information
Discussion
Discussion
Information
N/A
Information
STANDING REPORTS AT EACH REGULAR MEETING
STANDING REPORTS ONCE PER YEAR
April 2017 Jan-Mar 2017 14-15 June 2017 May 2017
Decision
Decision
28-29 Nov 2017 July-Aug 2017 Sept NoObj Oct 2017
Information
Discussion
Decision
Decision
Decision
N/A
Decision
Discussion
Discussion
Information
Decision
Decision
Decision
Discussion Discussion
Guidance
Decision
Guidance
Information

7 December 2016

02a Consent agenda Board Committee member appointments pdf

1



Board -2016 -Mtg -2-Doc 02a


Section A: Overview
Executive summary
1.1 This report sets out recommendations for Board and Committee
appointments , as considered by the Governance Committee at its
meetings on 14 October and 5 December 2016 .
1.2 Board Committee Chairs were consulted prior to the Governance
Committee meeting in relation to the nominations to their respective
Committees.
Recommendations
2.1 The Gavi Alliance Governance Committee recommends to the Gavi
Alliance Board :
a) That it appoint the following Board Members:
? Margaret (Peggy) Hamburg as an Unaffiliated Board Member in
the seat formerly held by HRH Infanta Cristina of Spain effective
immediately and until 3 1 December 2019 .
? Daniel Graymore of the United Kingdom as Board Member
repres enting the United Kingdom on the donor constituency
anchored by the United Kingdom effective immediately and until 31
December 2019.
? Shanelle Hall as Board member representing UNICEF in the seat
previously held by Geeta Rao Gupta effective immediately and until
her successor is appointed .
? Ummy Ally Mwalimu of Tanzania representing the developing
country constituency in the seat previously held by Seif Seleman
Rashid of Tanzania effective immediately and until 31 December
2017.
SUBJECT : CONSENT AGENDA: BOARD/COMMITTEE MEMBER
APPOINTMENTS
Agenda item: 02a
Category: For Decision
Authored by: Philip Armstrong, Joanne Goetz
Report to the Board
7-8 December 2016

7 December 2016

02b Consent agenda IRC nominations pdf

1



Board -2016 -Mtg -2-Doc 02b


Section A: Overview
Executive Summary
1.1 This report sets out recommendations for membership in the Independent
Review Committee (IRC).
Recommendations
2.1 The Gavi Alliance Governance Committee recommend ed to the Gavi
Alliance Board that it :
(a) Extend the terms of the IRC members listed in Annex A, Table 1 of
Document 02b for a further three -year term from 1 April 2017 until 31
March 2020;
(b) Ratify the emergency appointment of seven IRC members by the
Chief Executive Officer in concurrence with the Chair of the
Programme and Policy Committee (PPC) under Article 5.1.1 of the By -
Laws, whose names are listed in Annex A, Table 2 to Doc 02b , for a
term effective 14 October 2016 until 31 March 2019;
(c) Appoint as new IRC members the individuals listed in Annex A, Table
3 to Doc 02b for terms effective immediately until 31 March 2019.
Section B: Content
3.1 Under the G avi By -Laws, the IRC is an independent, impartial group of
experts that serves to guarantee the integrity and consistency of an open
and transparent funding process. The current IRC pool was formed in
2014 when the Secretariat requested an executive recruitment firm, Korn
Ferry, to conduct a tra nsparent and systematic search in order to refresh
and replenish the membership. Existing members were invited to re -apply,
and additional experts were recruited in order to provide deeper expertise
in the areas of gender and equity, logistics and cold cha in, and inactivated
polio vaccine (IPV). In order to avoid having to refresh or recruit the entire
pool at the same time, the end dates of members? terms were staggered:
SUBJECT : CONSENT AGENDA: IRC NOMINATIONS
Agenda item: 02b
Category: For Decision
Authored by: Adrien de Chaisemartin, Patricia Kuo
Report to the Board
7-8 December 2016

7 December 2016

02c Consent agenda Changes to Committee Charters pdf

1


Board-2016-Mtg-2-Doc 02c
Section A: Overview

Executive summary
1.1 Using the opportunity of the Board and Committee Self-evaluation that was initiated earlier in the year, with the findings to be presented to the
Governance Committee on 5 December and then to the Board on
7 December 2016, both the Audit and Finance Committee (AFC) and the
Investment Committee undertook comprehensive reviews of their
respective Committee Charters.
1.2 As more fully described below, these two Committees reviewed and evaluated their respective Charters against (i) the current work being
undertaken by these Committees and (ii) internationally accepted
standards and best practices.
1.3 The revised and updated Committee Charters of the AFC and Investment Committee follow substantially the existing terms of these two Charters but
with a number of amendments and revisions to the structure and with
greater and more specific elaboration on responsibilities and authorities for
purposes of clarity and precision.
Recommendations
2.1 The Gavi Alliance Governance Committee recommends to the Gavi Alliance Board that it: (a)
approve the revised and updated Committee Charter for the Audit and Finance Committee attached as Annex A to Doc 02c; and
(b)
approve the revised and updated Committee Charter for the Investment Committee attached as Annex B to Doc 02c.
SUBJECT : CONSENT AGENDA: CHANGES TO COMMITTEE
CHARTERS
Agenda item: 02c
Category: For Decision
Authored by: Philip Armstrong Report to the Board
7 - 8 December 2016

7 December 2016

02d Consent agenda Board Travel Policy review pdf

1



Board -2016 -Mtg -2-Doc 02d


Section A: Overview
Purpose of the report
1.1 This report provides an overview of proposed amendments to the Board
Travel Policy based on changes which ha ve been implemented recently in
relation to the policies for Gavi staff and consultants.
Recommendations
2.1 The Gavi Alliance Governance Committee recommends to the Gavi
Alliance Board that it approve amendments to the Board Travel Policy as
outlined in Annex A to Doc 02d .
Executive summary
3.1 In June 2016, the Gavi Board approved a revised policy which sets out the
criteria for travel reimbursement and support for Board members, Alternate
Board members and Committee delegates attending Gavi Board,
Committee and EAC meetings, and other Gavi related travel.
3.2 In September 2015, a revised travel policy for Gavi staff and consultants
was implemented and which includes changes in relation to the per diem
rates applied to cover the cost of meals not otherwise provided by Gavi. It
is proposed that the same rates be applied for Board and Committee
member travel to ensure consistency across the organisation and that the
Board Travel Policy be amended accordingly.
Risk implication and mitigation
4.1 Approval and implementation of the policy has enabled a possible
reputational risk to the Board to be mitigated as there is now a transparent
policy which was compiled following benchmarking with comparator
organisations in the public and private sectors.
SUBJECT : CONSENT AGENDA: BOARD TRAVEL POLICY REVIEW
Agenda item: 02d
Category: For Decision
Authored by: Philip Armstrong, Joanne Goetz
Report to the Board
7-8 December 2016

7 December 2016

02e Consent agenda Programme funding policy update pdf

1



Board -2016 -Mtg -2-Doc 02e
Report to the Board
7-8 December 2016


Section A: Overview
1. Executive summary
1.1. This report proposes changes to the Programme Funding Po licy in light of
the evolving operating model of Gavi that have been recommended by the
Audit and Finance Committee (AFC) at its meeting on 21 October .
1.2. Gavi?s Programm e Funding Policy aims to ensure the prudent management
of Gavi resources and commitments . The Policy was first approved by the
Board in June 2010 and various amendments have been subsequently
adopted.
1.3. This prop osal entails further modifications to better align with the emphasis
on providing support to countries more efficiently.
2. Recommendation
2.1 The Gavi Alliance Audit and Finance Committee has considered these
changes and recommends that the Gavi Alliance Board:
Approve the amended Gavi Alliance Programme F unding Policy attached
as Appendix 1 to Doc 02e .
Section B: Content
2.2 Context
2.3 Following approval by the Board of the new Health Systems and
Immunisation Strengthening (HSIS) policy in June 2016 , the introductio n of
the Cold Chain Equipment Optimisation Platform (CCEOP) , and the
emphasis on accelerat ing vaccine support for new programmes more
expeditiously and efficiently, the Secretariat has again reviewed the
Programme Funding Policy .
SUBJECT: CONSENT AGENDA: PROGRAMME FUNDING POLICY
UPDATE
Agenda item: 02e
Category: For Decision
Authored by:

Barry Greene, Managing Director, Finance & Operations
Tony Dutson, Senior Director Finance & CAO

7 December 2016

02f Consent agenda Programme funding request pdf

1



Board -2016 -Mtg -2-Doc 02f


Section A: Overview
Executive Summary
1.1 This paper requests the Gavi Alliance Board (?Board ?) to make a
programme funding decision related to the recommendations of the
20 -28 June 2016 Independent Review Committee ( ?IRC ?) as outlined in
Section B of this paper as well as to approve an additional amount for the
MenA bridge funding that the Board approved in June 2016 .
1.2 The funding required for th is decision includes US$ 68 million for five new
country vaccine programmes and US$ 2 million in Men ingitis A (?MenA?)
bridge funding for operational costs in 2017 , contingent on Board approval
of the principles set out in ?Gavi?s support for emergency vaccine stockpiles?
Board paper ( Figure 1 in Doc 13 ). These amounts have already been
provided for as anticipated future demand in t he financial forecast that was
reviewed by the Board in December 2015 and more recently by the Audit &
Finance Committee in October 2016.
1.3 The Audit and Finance Committee at its meeting on 21 October 2016 noted
that it had reviewed the financial implications of this and other potential
funding decisions that may be considered by the Board and concluded that
these decisions could be approved by the Board in accordance with the
Programme Funding Policy.
Recommenda tions
2.1 The Gavi Alliance Board is requested to:
Programmes
(a) Approve the recommendations of the June 2016 New Proposals IRC
for new country vaccine programme s to commence in 2017 and 2018 .


SUBJECT : CONSENT AGENDA: PROGRAMME FUNDING REQUEST
Agenda item: 02f
Category: For Decision
Authored by : Hind Khatib -Othman, Managing Director, Country Programmes
Report to the Board
7-8 December 2016

7 December 2016

02g Consent agenda Co financing waiver pdf

1



Board -2016 -Mtg -2-Doc 02g
Report to the Board
7-8 December 2016


Section A: Overview
Executive Summary
1.1 Investments made by Gavi countries in the co -procurement of their vaccines
have increased remarkably since the introduction of Gavi?s co -financing
policy , from US$ 21 million in 2008 to over US$ 113 million in 2014. In spite
of this overall positive trend, two countries, South Sudan and Yemen , have
defaulted on their 2015 co -financing obligations and therefore, as per the
co -financing policy, would normally see all Gavi support suspended at the
end of 2016. Both have formally requested Gavi to continue its support in
spite of their default status on their 2015 co -financing obligations .
1.2 South Sudan, which emerged from a protracted civil war as an independent
State in 2011 , witnessed a sharp and rapid deterioration in th e political and
security situation in 2016, with renewed concerns about a possible
resumption of large -scale hostilities. Yemen also has been affected by
internal and external conflicts since January 2015, which has inhibited its
ability to co -finance G avi -supported vaccines. Gavi?s co -financing policy
stipulates that the Board may consider waiving default sanctions under
exceptional circumstances. The PPC has considered the evidence and a
number of elements (see sections B and C) to guide the judicious
app lication of such exceptions, and has recommended that the Board
approve the continuation of Gavi support in those countries irrespective of
their default status on their 2015 co -financing obligations.
Recommendations
2.1 The Gavi Alliance Programme and Policy Committee recommend ed to the
Gavi Alliance Board that it :
Find that exceptional circumstances in South Sudan and Yemen justify the
continuation of Gavi support in those countries irrespective of their default
status on their 2015 co -financing obligations.
SUBJECT: CO -FINANCING WAIVER
Agenda item: 02g
Category: For Decision
Authored by: Santiago Cornejo, Jhoney Barcorolo, Laura Boonstoppel,
Maria Patyna

7 December 2016

02h Consent agenda Country Engagement Framework pdf

1



Board -2016 -Mtg -2-Doc 02h
Report to the Board
7-8 December 2016


Executive Summary
1.1 At the June 2016 Board meeting, the Secretariat presented initial ideas to
introduce a new approach for countries in the context of the new Health
System and Immunisation Strengthening (HSIS) Framework.
1.2 The attached PPC paper p rovides an update on the des ign of this new
approach, referred to as the Country Engagement Framework (?CEF?),
which seeks to more efficiently channel Gavi support to countries, in a
manner better suited to country needs and timelines, while assuring
independent and rigorous review, and to optimise programming to achieve
more equitable and sustainable immunisation coverage.
1.3 In October, the PPC was presented with implementation progress to date
and was asked to consider certain flexibilities regarding mechanisms for
providing independ ent recommendations on Gavi's investments. These
adjustments, described in Section 7 of the attached paper, are designed to
address some of the limitations of a Geneva and document -based review
process and will allow further learning opportunities in 2017 as the new CEF
approach is further refin ed. The PPC members welcomed the CEF
approach being taken by the Alliance.
1.4 Lessons from t he implementation of the proposed adjustments to the review
mechanisms will be presented to the PPC at its next meeting in May 2017
before finalising any requests for changes to review processes for Board
decision by the end of 2017.
Recommendations
2.1 The Ga vi Alliance Programme and Policy Committee recommended to the
Gavi Alliance Board that it:
(a) Approve certain adjustments to the existing methods of reviewing and
approving new Gavi support to facilitate and inform a learning agenda
for an updated review and approval process, including:
SUBJECT : COUNTRY ENGAGEMENT FRAMEWORK
Agenda item: 02h
Category: For Decision
Authored by: Sarah Churchill, Alan Brooks, Anna Standertskjold

7 December 2016

03 2016 2020 Strategy Implementation and progress document pdf

1



Board -2016 -Mtg -2-Doc 03

Section A: Content
A new reporting structure
1.1 This document is the first update on progress against the 2016 -2020
strategy. Going forward, strategy progress updates will be provided at each PPC
and Board meeting in a format that provides a consistent view on progress made,
how challenges are being addressed, and will contain the latest available data .1
The strategy progress update uses the indicators in the G avi 2016 -2020 strategy
and Alliance Accountability Framework (AAF) to track progress towards strategy
goals and to monitor the performance of the Alliance, Secretariat, Partne rs and
countr ies . These indicators are summarised in Strategy and Alliance KPI
da shboards (see appendix for full size versions) . Colour -coded references to the
relevant indicators in the dashboard are included throughout the paper.

1.2 As the Alliance is in the first year of the strategy period, data on progress for
Strategy Indicators is not yet available , but progress on Alliance KPIs has been
included. Where data is not yet available for Alliance KPIs , projections and
estimates have been included to provide indication of progress and/or issues.
The dashboards indicate where prelimina ry data is being used in place of final
values.
1.3 This progress update is supported by a set of linked papers, as requested by the
Board, which should be considered together with this document. The Country
Programmes (CP) update provides a summary of develop ments in key countries
and an overview of how the Alliance's investments, technical support and grant
and risk management come together at a country level to achieve strategic goals

1 Throughout the document, data is referenced from Strategy Indicators, Alliance KPIs and Secretariat
Performance Management (CPM and TPM)
SUBJECT : 2016 -2020 STRATEGY: IMPLEMENTATION AND
PROGRESS
Agenda item: 03
Category: For Information
Authored by: Nicolas Theopold, Roice Fulton, Adrien de Chaisemartin, Alex
de Jonquieres, Mirjam Clados, Johannes Ahrendts
Report to the Board
7-8 December 2016

7 December 2016

04 CEO s report document pdf

1



Board -2016 -Mtg -2-Doc 03
Report to the Board
7-8 December 2016


30 November 2016
Dear Board members
I am finalising this report from rural Madagascar where I have witnessed some of
the challenges countries face in strengthen ing their immunisation programmes.
Madagascar has among the highest poverty levels in the world with over 75% of
the population living on less than US$ 1.90 per day (based on 2012 data ? the
latest for which it is available) . Following a sustained period of political crisis, it
remains fragile with large inequities and weak systems . There are particular
challenges in rural areas with limited resources flowing from central level . The
government reports coverage of 85 % 1 nationwide but it is clear when you visit
communities that this is far from reality . Most clinics have only one healthworker
(who must close the facility for activities such as outreach, training and collecting
vaccines), many lac k working cold chain equipment and other infrastructure , and
they face regular stockouts due to supply chain challenges . The country has
conducted eight polio campaigns in the past two years after cases of vaccine -
derived polio virus were detected, and thi s has also diverted healthworkers from
routine immunisation. From the President and First Lady, to the Prime Minister
and Minister of Health , and down to community healthworkers, everyone we met
showed a strong commitment to immunisation and a willingness to address these
challenges . The Alliance has scaled up its support (described below) but this was
a timely reminder of the challenges we all face to achieve our 2016 -20 20 goals.
The last two years have been a period of inten se change for the Alliance. We
developed the 2016 -20 20 strategy, secured renewed backing from donors at the
Berlin Replenishment, reviewed and modified many of our policies to support the
new strategy, developed new approaches in key areas, redesigned how the
Alliance operates wit h the Partners? Engagement Framework (PEF) , introduced a
new accountability framework, zero -based partner and Secretariat budgets , and
introduced a new risk policy and risk management approach with a si gnificant
scale -up in resourc es . W e have largely completed this process and are now

1 Unless otherwise noted, all references to immunisation coverage and under -immunised children
in this report refer to the number of children receiving three doses of DTP -containing vaccine
Report of the Chief Executive Officer

7 December 2016

05 Financial forecast and programme funding envelopes Appendix 3 4 pdf






Appendix 3 : Update on resources and expenditures in 2016 and 2017
1 Resources
1.1 The Total cash inflows in 2016 are predicted to be 1 02 % of the amount projected
in December 2015, the increase being due mainly to additional direct
contributions. In January through September , 7 7% of the projection for all of 2016
was realised, compared to 75 % over the similar period in 2015.
Resource projections for 2016 and 2017

2 Expenditure
2.1 Disbur sements for programme s in 2016 are predicted to be 86 % of the amount
projected in December 2015, to reflect the results of programme approvals and
endorsements in 20 16 and updated assumptions on disbursement timing. In
January through September , 52% of th e projection for all of 2016 was realised,
compared to 61 % over the similar period in 2015. A breakdown of disbursements
by Programme is included in Annex 2, Figure 2 of document AFC -2016 -Mtg -4-
Doc 02 .









Resources
US$ millions
Dec-2015
Boa rd
Proj ecti on
Actual:
YTD Sept-16
% of
Proj ecti on
for yea r
Dec-2016
Boa rd
Proj ecti on
Dec-2015
Boa rd
Proj ecti on
Dec-2016
Board
Projection
Direct contributions - confirmed 1,471 1,117 76% 1,460 1,427 1,442
Direct contributions for IPV 97 93 96% 93 79 77
IFFIm Proceeds 100 0 0% 100 300 150
AMC Proceeds 100 107 107% 131 47 89
Investment Income 36 56 156% 50 36 25
Other * 0 15 0
Total Inflows 1,804 1,388 77% 1,834 1,889 1,783
For Res ources , the Proj ected a mount i s per the l a tes t foreca s t pres ented to the Boa rd before the s ta rt of the yea r
* 'Other' compri s es unrea l i s ed FX ga i ns /(l os s es ) a nd ti mi ng a dj us tments
2017 2016

7 December 2016

05 Financial forecast and programme funding envelopes document pdf




Board -2016 -Mtg -2-Doc 05 1
Report to the Board
7-8 December 2016


Section A: Overview
1 Executive summary
1.1 This report informs the Gavi Alliance Board (?Board ?) of the updated Gavi
financial forecast for 2016 -202 5 and provides an update on resources and
expenditures in 2016 and 2017 . (See section B)
1.2 It also requests the Board to approve programme funding envelope s to be allotted
to individual programmes by the Secretariat, in accordance wi th the Programme
Funding Policy, as follows :
(a) An envelope for Vaccine programmes and Health Systems and
Immunisation Strengthening (HSIS) programmes ; and
(b) An envelope for Cold Chain Eq uipment Optimisation Platform (CCEOP )
programmes , in order to operationalise the recommendation of the
Programme and Policy Committee to allow multi -year commitments to be
entered into before June 2017 , up to a maximum of US$ 250 million .
1.3 The forecast indicates that all the decisions recommended for approval at this
Board meeting can be made in acco rdance with the Programme Funding Policy.
The financial implications of these decisions are summarised in Figure 1 , which
also indicates potential future investments yet to be considered .
1.4 With regard to expenditure, the forecast provides for all currently anticipated
expenditure needs through 2025. It incorporates all prior funding decisions 1 and
those requested at this Board meeting, and provides for future requests based
on the latest demand estimates.
1.5 With regard to resources, the forecast includes the amounts pledged date
including those made in Berlin i n January 2015 and subsequently . It includes an
allow ance for f urther contributions expected as donors complete their pledging
through 2020 and contribute their pledges.

1 Including the decision of th e Executive Committee in November 2016 to approve a vaccine purchase
agreement that c ould add approximately US$ 50 million to Gavi?s estimated expenditure for 2016 -2021.
SUBJECT: FINANCIAL FORECAST & PROGRAMME FUNDING
ENVELOPES
Agenda item: 05
Category: For Decision
Authored by: Barry Greene, Managing Director, Finance & Operations
Tony Dutson, Senior Director Finance & CAO

7 December 2016

06 Partners Engagement Framework document pdf

1



Board -2016 -Mtg -2-Doc 06


Section A: Overview
Purpose
1.1 The purpose of this report is to update the Board on the progress of the
implementation of the Partners? Engagement Framework (PEF) .
Background
2.1 The PEF is the new way of planning, funding, operationali sing and
monitoring technical assistance (TA) to countries , by leveraging the
comparative strength of partners, both existing and new, as well as funding
activities of core partners for setting global norms and standards in
immunisation. The new PEF archite cture was approved by the Board in
2015 and entails a significant evolution from the previous Business Plan
model in 2011 -20 15 .
2.2 The PEF has progressed from design to implementation in 2016. This has
been a major paradigm shift, and Alliance partners, particularly WHO and
UNICEF, are working closely with the Secretariat to realise the spirit of the
PEF, marked by strong country focus , transparency and accountability.
2.3 So far in 2016 , the Secretariat and Gavi partners have worked under the
guidance of the PEF Management Team (MT) to finalise roles, resources
and accountability across Gavi partners. Memorand a of Understanding
(MoUs) have been signed and include the set of activities that partners will
perform under the three key componen ts of the PEF : 1) Foundational
Support, 2) Targeted Country Assistance (TCA) , and 3) Strategic Focus
Areas (SFAs ).
2.4 Following the sign ing of MoUs, WHO, UNICEF, World Bank and the US
Centers for Disease Control (CDC) have started to implement activities and
initiated restructuring of processes/structures within their organisation s to
SUBJECT : PARTNERS? ENGAGEMENT FRAMEWORK
Agenda item: 06
Category: For Information
Authored by: Adrien de Chaisemartin, Caroline Dubois , Meegan Murray -
Lopez
Report to the Board
7-8 December 2016

7 December 2016

07 Country presentation Cote d Ivoire No paper pdf

1



Board -2016 -Mtg -2-Doc 07
Report to the Board
7-8 December 201 6





SUBJECT: COUNTRY PRESENTATION ? C?TE D?IVOIRE
Agenda item: 07
No paper

7 December 2016

07a Country Programmes strategic issues document pdf

1



Board -2016 -Mtg -2-Doc 07a
Report to the Board
7-8 December 2016

Section A: Overview
Executive Summary
1.1 This paper is one of two papers ( 07 a and 07 b) on strategic issues relevant
to Gavi?s Country Programmes . This paper, p aper 07 a, provides key
highlights from the Alliance's in -country work that have emerged since the
last update on Country Programmes to the Board ( more detailed information
on the Alliance's in -country operations, activities, achievements and
challenges, is provided in Appendices A through F). As requested at the last
Programme and Policy Committee (PPC) and Board meetings in May and
June 2016 paper 07 a also provides a n overview of how the Alliance's
investments, technical support and grant and risk management all come
together to help strengthen coverage and equity, ensure sustainability, and
better manage risk in countries. Paper 07 b asks the Board to ta ke a strategic
decision with respect to additional funding for the Cold Chain Equipment
Optimisation Platform.
Key programme and country updates
2.1 This section provides key highlights from the Alliance?s in -country work ,
focus ing on major developments across the portfolio. A n overview of
performance across the Gavi portfolio of countries against the Alliance?s
strategy is provided in Doc 03 . Going forward, the Secretariat will explore
how to make available to the Board a systematic update on progress in
every Gavi country.
2.2 Nigeria is one of the most challenging countries in Gavi?s portfolio . It has
the second highest number of under -immuni sed children in the world and
DTP3 coverage is below 60%. Recent developments , inclu ding a measles
campaign which achieved only 84.5% coverage, and the discovery of four
case of wild poliovirus which had been circulating undetected since 2011 ,
illustrate the weakness of the immunisation programme . The recent
extended audit identified sign ificant misuse and systematic weaknesses,
and is yet to be fully closed . Moreover, the country will enter accelerated
transition in 2017. To address these issues , the Gavi CEO and Global Fund
Executive Director visited Nigeria in July to meet with His Exce llency the
President, the Minister of Health and the Minister of Finance. During this
SUBJECT : COUNTRY PROGRAMMES : STRATEGIC ISSUES
Agenda item: 07a
Category: For Information
Authored by: Hind Khatib -Othman

7 December 2016

07b Country Programmes Cold Chain Equipment Optimisation Platform CCEOP pdf

1



Board -2016 -Mtg -2-Doc 07b
Report to the Board
7-8 December 2016

Section A: Overview
Executive Summary
1.1 In June 2015 the Board approved the establishment of the Cold Chain
Equipment Optimisation Platform ( CCEOP ) to strengthen country cold chain
systems and to advance the Alliance?s Supply Chain Strategy .
Improvements in the cold chain are a vital building block towards delivering
vaccines more equitably and to increasing vaccine coverage , while shifting
towards m ore reliable, energy efficient, environmentally ?green?, and
sustainable equipment . Improvements in cold chain are also among the
most effective interventions the Alliance can make to mitigate risks to its
vaccine investments of over US $ 1 billion per year . In addition, the CCEOP
has contributed to promis ing market shaping developments .
1.2 The 2015 Board decision noted that an amount of US$ 50 m illion would be
allocated to launch the CCEOP and fund the initial applications in
2016 -2017 and that this would be reassessed and potentially increased
based on initial applications . Since the CCEOP was launched, 15 countries 1
have had proposals approved, recommended for approval by the
Independent Review Committee (IRC) or are under review via the Country
Engagement Process ( CEF ), totaling requests for US$147 m illion in
CCEOP support 2 from Gavi over five years. As of end November, 12
countries have been approved or recommended for approval. The total
CCEOP support requested by these 12 countries in 2017 is up to a
maximum of US$ 49.3 m illion , and US$ 133.7 m illion over five years. Eight
of these country proposals were recommended in the fourth quarter of 2016,
reflecting 68% of the requested support and the accelerating demand from
countries. Thr ee other proposals are under review via CEF with an
estimated maximum CCEOP request of US$ 6.1 m illion in 2017, and a total
from the CCEOP of US$ 12.9 m illion over five years. The Board is therefore
being asked to deci de whether to allocate additional fund ing to the Cold

1 Haiti, DRC, Uganda, Cameroon, Kenya, Niger, Madagascar, Pakistan, South Sudan, Uzbekistan,
Guinea, Liberia, Malawi, Togo, Sierra Leone 2 The total value of the proposed cold chain investments is US $ 213 million with countries? joint
investments of US $ 67 million .
SUBJECT : COUNTRY PROGRAMMES: COLD CHAIN EQUIPMENT
OPTIMISATION PLATFORM (CCEOP)
Agenda item: 07b
Category: For Decision
Authored by: Hind Khatib -Othman , Alan Brooks, Hamadou M. Dicko ,
Olamide Folorunso

7 December 2016

08a Fragile settings emergencies and displaced people document pdf

1

Board -2016 -Mtg -2-Doc 08a
Report to the Board
7-8 December 2016


SUBJECT: FRAGILE SETTINGS AND EMERGENCIES
Agenda item: 08a
Category: For Decision
Authored by:
Aur?lia Nguyen, Judith Kallenberg, Anna -Carin Matterson,
Riswana Soundardjee, Antonia Pannell, V?ronique maeva
Fages, Anne Cronin, Kristine Brusletto
1. Purpose
1.1 This paper is one of two papers (08a and 08b) for agenda item 08. The current
paper (08a) presents PPC recommendations on principles for a new policy
guiding Gavi?s approach in fragile settings, emergencies, and situations
involving displaced people. Paper 08b asks the Board to take a strategic
decision with regards to potential engagement with lower -middle -income
countries (LMICs) that are fragile or face protracted emergencies but whose
eligibility for Gavi support cannot be exactly determined because a point
estimate for Gross National Income (GNI) per capita is not available . Currently
this question only arises in the case of Syria.
1.2 During its last meeting, the PPC was presented with findings from a review of
Gavi?s current approach to supporting immunisation in fragile and emergency
settings and proposed changes going forward (see Appendix A). The PPC
endorsed a set of principles to form the basis for an updated policy 1, and
encouraged a clear separation between fragility, emergencies and displaced
people, as is reflected in this paper. 2
1.3 The PPC also recommended that the Board decide on how to engage with
lower -middle -income countries that are fragile or face protracted emergencies.
In those countries experiencing protracted emergencies that fall outside Gavi
eligibility (e.g. Libya and Iraq 3), the PPC recommended no Gavi engagem ent
as they did not think it appropriate to reopen Gavi eligibility at this time. It was
noted that PPC members representing the CSO and Research & Technical
Health Institutes constituencies expressed support for Gavi engagement in
these settings.
1 Of note, this policy would not cover the individual institutional efforts of Alliance partners operating in
fragile settings and emergencies. Throughout this document, ?Gavi? refers to the Alliance operating with
Gavi funds and within the Gavi Alliance ma ndate. 2 PPC members underlined that the process of the policy review had been faster than usual due to the
perceived urgency of (re -)defining Gavi?s approach in this area. 3 Both currently upper middle -income countries

7 December 2016

08b Potential Gavi support for immunisation in Syria pdf

Report to the Board
7-8 December 2016
1




Board -2016 -Mtg -2-Doc 08b

SUBJECT: POTENTIAL GAVI SUPPORT FOR IMMUNISATION IN
SYRIA
Agenda item: 08b
Category: For Decision
Authored by: Aur?lia Nguyen, Judith Kallenberg, Anna -Carin Matterson,
Antonia Pannell
Section A: Overview
1. Purpose
1.1 The purpose of this paper is to ask the Board to take a strategic decision
with regards to potential engagement with lower -middle -income countries
(LMICs) that are fragile or face protracted emergencies but whose eligibility
for Gavi support cannot be exactly determined because a point estimate for
Gross National Income (GNI) per capita is not available . Currently this
question only arises in the case of Syria. This paper includes information on
Syria?s income stat us as relevant to Gavi?s eligibility policy, the current
situation in Syria including immunisation needs, and options for Gavi
engagement.
2. PPC discussions
2.1 The Programme and Policy Committee (PPC) discussed this issue at its
meeting on 25 -26 October 2016 . PPC members were generally supportive
of engagement with Syria, however they acknowledg ed that there is
uncertainty about its eligibility status . They suggested the Secretariat
explore further information to ascertain Syria ?s eligibility status to the extent
possible and that it would be important to consult the World Bank on this
matter. They also suggested further exploring what the comparative
advantage might be for Gavi to support immunisation in Syria, and how such
support might be operationalised.
2.2 In those countries experiencing protracted emergencies that fall outside
Gavi eligibility (e.g. Libya and Iraq 1), the PPC recommended no Gavi
engagement as it did not think it appropriate to reopen eligibility at this time .
It was noted that PPC members representing the CSO and Research &
Technical Health Institutes constituencies expressed support for Gavi
engagement in these settings.
1 Both currently upper middle -income countries

7 December 2016

09 Chair s reflections on the day No paper pdf

1



Board -2016 -Mtg -2-Doc 09
Report to the Board
7-8 December 201 6





SUBJECT: CHAIR?S REFLECTIONS ON THE D AY
Agenda item: 09
No paper

7 December 2016

10 Chair s overview No paper pdf

1



Board -2016 -Mtg -2-Doc 10
Report to the Board
7-8 December 201 6





SUBJECT: CHAIR?S OVERVIEW
Agenda item: 10
No paper

7 December 2016

11 Risk management update document pdf

1



Board -2016 -Mtg -2-Doc 11


Section A: Overview
Executive Summary
1.1 Gavi has now largely implemented the key changes to strengthen risk
management and assurance practices approved by the Board in December
2014. This has resulted in significantly enhanced risk management
capabilities and tools, which are now being scaled up and institutionalised
in day -to -day management. The Board has indicated a desire for more
content -focused strategic risk discussions going forward.
1.2 As a basis for these discussions, and as requested by the Board during its
April 2016 Retreat , the Secretar iat has worked with partners to develop a
Risk & Assurance Report which sets out the Alliance?s current exposures to
the critical risks that could potentially impact its ability to achieve its mission
and strategic goals. Out of all risks identified, 15 we re ranked as either
?high? or ?very high? risks , based on their potential impact and / or likelihood
of occurrence given current mitigation . The Gavi Alliance Board is
requested to approve the report , agreeing with the top risks identified , and
to have a strategic discussion on risk based on the content of the report,
guided by the following questions:
(a) Is the Gavi Alliance Board comfortable with the design of the report as
the basis for an annual in -depth discussion on the Alliance?s risk
exposure, control s and assurance ?
(b) Do Gavi Alliance Board members have any initial feedback on risk
appetite for these top risks as input for the 2017 update of the risk
appetite statement? Is current exposure to any risk clearly outside
Gavi?s risk appetite ?
(c) Do any of th ese risks require a more in -depth discussion or deep -dive
by the Gavi Alliance Board in a future Board meeting or retreat?
SUBJECT : RISK MANAGEMENT UPDATE
Agenda item: 11
Category: For Decision
Authored by: Jacob van der Blij , Alex de Jonqui?res
Report to the Board
7-8 December 2016

7 December 2016

12 Review of Gavi support for HPV vaccine document pdf

1



Board -2016 -Mtg -2-Doc 12


Executive Summary
1.1 Rationale
(a) Human papillamovirus (HPV) is the primary cause of cervical cancer,
a disease which results in 266,000 deaths annually (GLOBOCAN
2012). There is a disproportionate burden in low and middle -income
countries, where 85% of these deaths occur. Based on the latest
available data, cervical cancer may now cause more deaths among
women worldwide than childbirth.
(b) The Gavi Board decided in November 2011 to open a funding window
to support HPV vaccination in Gavi -eligib le countries. This decision
supported HPV vaccination through one of two pathways, depending
on the country situation: either national introduction or a demonstration
programme with limited geographic and target population scope . The
latter approach was i Q W H Q G H G W R I D F L O L W D W H ? learn ing by doing" and allow
less -experienced countr ies to prepare for a national scale -up (which
required a second application to Gavi) .
(c) As of Sept ember 2016, 23 countries have implemented a
demonstration programme, proving the fea sibility of implement ing
HPV programmes in low income countries and generating globally
applicable lessons . Three countries (Rwanda, Uganda and Honduras)
have introduced HPV vaccination in their national immunisation
programmes.
(d) Overall, Gavi has achieved its goal to vaccinate 1 million girls by 2015.
However, there is a risk that the Alliance will not meet the target of
vaccinating 30 million girls by 2020 , due to delays in national
introductions. Lessons learned indicate that the demonstration
programme d esign contributed to these delays in three primary ways.
First, the high level of financial support provided for demonstration
programmes and an emphasis on achieving high coverage rates did
not encourage countries to test more cost -sustainable and
program matically effective delivery models to inform and prepare for
SUBJECT : REVIEW OF GAVI SUPPORT FOR HPV VACCINE
Agenda item: 12
Category: For Decision
Authored by: Anissa Sidibe, Stephen Sosler and Michael F Thomas
Report to the Board
7-8 December 2016

7 December 2016

13 Gavi s support for emergency vaccine stockpiles document pdf

1



Board -2016 -Mtg -2-Doc 13
Report to the Board
7-8 December 2016

Executive Summary
1.1 Rationale
(a) Disease outbreaks in Gavi -supported countries are a growing concern,
two recent examples being Ebola and yellow fever . Outbreaks are
often symptoms of weaknesses in routine immunisation and health
systems. For diseases with limited vaccine supply, maintain ing
stockpiles facilitate s rapid and equitable access to vaccines in an
outbreak situation.
(b) Gavi currently supports three emergency vaccine stockpiles: yellow
fever, meningitis and cholera. 1 Each stockpile is managed by an
International Coordinating Group (ICG) 2 which makes annual
decisions on stockpile size and determines how dose s should be
allocat ed in response to country requests . The ICG is supported by a
Secretariat at WHO. Gavi provides funding for : (1) vaccine costs ; (2)
operational costs ; and (3) WHO staff to support the ICGs and serve as
disease focal points. From 2006 -2015, Gavi has disbursed
approximately US$ 90 million in vaccine and operatonal cost support
for the three stockpiles, making available over 70 million doses of
vaccine.
(c) Emergency v accine stockpile s have been an essential and effective
mechanism to support countries in respond ing to outbreaks . However,
Gavi?s investments have been made incrementally and without a
systematic approach to design, implementation and accountability .
Through t his review , opportunities have been identified for Gavi to
enhance the impact of its stockpile investments through a more
consistent approach which is aligned to broader disease control

1 Gavi has also committed to fund a future stockpile of Ebola vaccines; this was beyond the scope
of the review and the applicability of the recommendations to Ebola will be assessed at the time of
future investment decision -making. 2 The ICG is composed of a representative from four member organisations: International
Federation of Red Cross and Red Crescent Societies (IFRC); Medecins Sans Frontieres (MSF);
UNICEF; and WHO. For cholera, the ICG only manages the emergency component of the stockpile ,
while no n-emergency use is coordinate d through the Global Task Force on Cholera Contol
(GTFCC), of which the Gavi Secretariat is a member .
SUBJECT : GAVI?S SUPPORT FOR EMERGENCY VACCINE
STOCKPILES
Agenda item: 13
Category: For Decision
Authored by: Aurelia Nguyen, Wilson Mok, Melissa Ko, Patience Musanhu,
Stephen Sosler

7 December 2016

14 Gavi s continued role in Yellow Fever control document pdf

1



Board -2016 -Mtg -2-Doc 14
Report to the Board
7-8 December 2016


Executive Summary
1.1 Rationale
(a) The recent Yellow Fever (YF) outbreaks in Angola and D R Congo , and
subsequent cross -border and intercontinental spread of the virus ,
underline the global public health threat that YF re presents . YF virus
is endemic in 47 African countries , 30 of which are Gavi -eligible, as
well as 13 non -Gavi eligible countries in Central and Latin America.
Moreover, factors facilitating YF virus transmission are evolving and
thus the risk of YF outbreaks is increasing , particularly in urban
env ironments. Th ese factors include the widening distribution of the
Aedes vector, increasing rates of urbani sation, population movements ,
ease of travel, climate change , increasing exposure of humans to
infected mosquitoes and growing numbers of unimmuni sed
individuals , the latter due in part t o low levels of routine immunisation .
The risk of outbreaks can be substantially reduced by increasing
population immunity to >70% , which will be achieved through a wide
age -range campaign and subsequent introduction into routine
immunisation with high coverage.
(b) Gavi has a long -standing commitment to YF control and since the
Alliance?s creation in 2000 has invested nearly US $ 300 mil lion ,
supporting the vaccination of over 200 million people in Africa . Gavi?s
investments have been aligned with WHO -recommended vaccination
strategies and have supported the introduction of Y F vaccine into
routine immuni sation programmes (17 countries to date ), the
implementation of wide -age range mass preventive vaccination
campaigns in high -risk countries ( 14 countries ) and access to the
emergency vaccine stockpile to rapidly resp ond to confirmed YF
outbreaks (1 6 countries)
(c) Experiences in W est Africa illustrate the effectiveness of this three -
pronged strategy to prevent YF outbreaks when effectively
implemented. Since 2006 when Gavi?s support for mass preventive
campaigns began, no YF outbreaks have been detected in W est
SUBJECT : GAVI ?S CONTINUED ROLE IN YELLOW FEVER CONTROL
Agenda item: 14
Category: For Decision
Authored by: Patience Musanhu, Stephen Sosler and Michael F Thomas

7 December 2016

15 Committee Chair and IFFIm Board reports pdf

1



Board -2016 -Mtg -2-Doc 15
Report to the Board
7-8 December 201 6

















SUBJECT: COMMITTEE CHAIR AND IFFIM BOARD REPORTS
Agenda item: 15
To follow

7 December 2016

16 Review of decisions No paper pdf

1



Board -2016 -Mtg -2-Doc 16
Report to the Board
7-8 December 201 6





SUBJECT: REVIEW OF DECISIONS
Agenda item: 16
No paper

7 December 2016

17 Closing remarks and any other business No paper pdf

1



Board -2016 -Mtg -2-Doc 17
Report to the Board
7-8 December 201 6





SUBJECT: CLOSING R EMARKS AND ANY OTHER BUSINESS
Agenda item: 17
No paper

7 December 2016

A Annual report on implementation of the Gender Policy pdf

1



Board -2016 -Mtg -2-A
Report to the Board
7-8 December 2016


Section A: Overview
Executive Summary
1.1 This report aims to update the Gavi Board on progress in 2016 in
implementing the Gavi Gender Policy , which spans programm atic ,
corporate, and gover nance dimensions of Gavi?s work .
Recommendations
2.1 This report is for information only.
Section B: Content
Context
3.1 The purpose of Gavi?s Gender Policy is to support countries to increase
coverage by overcoming gender -related barriers to accessing immunisation
services by promoting equal access and utilisation f or all boys and girls.
3.2 Gender -related barriers are obstacles to the access and utilisation of
health services that are related to social and cultural norms about men and
women?s roles. Mothers tend to be the primary caretakers of children and i n
societies where women have low status, their children ? both girls and boys
? are less likely to be immunised. When women are empowered,
immunisation coverage increases.
3.3 Gender is one of the core components of Gavi?s commitment to equity in
immunisation, and it cuts across all aspects of equity and health. Evidence
shows that gender gaps remain and disparities increase when gender is
combined with poverty and other drivers behind exclusion.
SUBJECT : ANNUAL REPORT ON IMPLEMENTATION OF THE
GENDER POLICY
Agenda item: A
Category: For Information
Authored by: Meegan Murray -Lopez

7 December 2016

Gavi Alliance Board Minutes 7 8 December 2016 PDF

Board -2016 -Mtg -02 1
Minutes



Gavi Alliance Board Meeting
7-8 December 2016
Sofitel Abidjan Hotel Ivoire, Abidjan, C ?te d?Ivoire


1. Chair?s report

1.1 Finding a quorum of members present, the meeting commenced at 09.19 local
time on 7 December 201 6. Ngozi Okonjo -Iweala , Board Chair , chaired the
meeting .

1.2 The Chair welcomed new Board member s and Alternate Board member s, as well
as Rob Moodie, Chair of the Evaluation Advisory Committee . She shared regrets
from Ren? Karsenti, Chair of the IFFIm Board, who had been unable to attend due
to other commitments. She noted that departing members would be recognised
for their service at the dinner that evening.

1.3 The Board met in closed session on the evening of 6 December and the morning
of 7 December to discu ss a number of items including potential Gavi engagement
in Syria, the Board an d Committee self -evaluation and to review the CEO ?s
performance.

1.4 Standing declar ations of interest were tabled to the Board (Doc 01a in the Board
pack). The Chair noted that in the context of the items for decision on the agenda ,
there were a number of Board member s who would have conflicts of interest and
that these would be raised at the appropriate time and recorded in the applicable
parts of the minutes.

1.5 The Board noted its minutes from 22 -23 June 2016 (Doc 01b), which were
approved by no objection on 22 September 201 6. The Board also noted its
workplan (Doc 01c) and the Chair e ncouraged Board members to contribute to the
forward plan by raising issues which they may wish to add either with her directly
or with the Secretariat . She had solicited inputs to the agenda for this meeting but
had only received two responses. It is plan ned that further work will be done to
identify the best process for eliciting input of Board members.

1.6 The Chair informed Board members that the Secretariat continues to work on the
quality of the Board meeting materials and that the e xecutive summaries for the
papers requiring decisions continue to be condensed and are easier to read.
Considerable additional material related to the topics on the agenda can be
access ed on myGavi for those wishing to receive more comprehensive
informatio n.

1.7 Finally, the Chair informed Board members that the Executive Committee had only
met once since the last Board meeting, on 1 November 2016, to consider a
commercially sensitive decision regarding a rotavirus vaccine.

Presentations

7 December 2016

03 2016 2020 Strategy Implementation and progress presentation pdf

www.gavi.org
2016 -2020 STRATEGY :
IMPLEMENTATION
AND PROGRESS
Reach every child
Seth Berkley
7 December 2016, C?te d?Ivoire
The Alliance accountability framework
2 Gavi Board meeting 7 December 2016
Foundation for strategy
progress update

7 December 2016

04 CEO s Report presentation pdf

www.gavi.org
CEO Board update
Immunising children together
Seth Berkley, MD
7th December 2016, C?te d?Ivoire
Global landscape Reporting back on Board decisions Health security on the agenda Alliance fit for purpose
Gavi Board meeting
7 December 2016
2
Global
landscape
2 Reporting back on
Board decisions
1 Health threats
3 Alliance fit
for purpose
4

7 December 2016

07 Country presentation Cote d Ivoire pdf

Conseil d ?Administration de Gavi
SOFITEL HOTEL IVOIRE, Abidjan, du 07 au 08 d?cembre 2016
Programme Elargi de Vaccination (PEV) en C?te d ?Ivoire :
Situation, progr?s, perspectives en 2016
Dr Raymonde GOUDOU COFFIE
Ministre de la Sant? et de l ?Hygi?ne Publique
Abidjan, le 07 d?cembre 2016

7 December 2016

12 Review of Gavi support for HPV vaccine presentation pdf

www.gavi.org
REVIEW OF GAVI SUPPORT
FOR HPV VACCINE
BOARD MEETING
Michael F Thomas
7 -8 December 2016, Abidjan, C?te d?Ivoire
2
Board meeting
7-8 December 2016
Human Papillomavirus (HPV) is the principal
causative agent of Cervical Cancer (CC)
CC is a leading cause of cancer death in women
? 266,000 women die of this disease every year and this
number is rising
? 85% of the disease burden is in developing countries
HPV vaccines are innovative and offer an
opportunity to reduce disease burden
? HPV is the second cancer -causing disease to be vaccine
preventable
? The two vaccines currently available prevent 70% of disease
HPV vaccines are available at an affordable price to
Gavi -eligible countries
CONTEXT: CERVICAL CANCER AND THE HPV
VACCINES

7 December 2016

15c IFFIm Company Chair report pdf

IFFIm CHAIR REPORT
The International Finance Facility for Immunisation
GAVI BOARD MEETING
Ren? Karsenti, Chair IFFIm Board of Directors
7 -8 December 2016, Abidjan, C?te d?Ivoire
1. Funding Gavi
2. IFFIm US$ 500 million Floating Rate Note (FRN)
3. IFFIm?s continued strategic role
4. Other potential uses of the IFFIm model
2
Last updated: 24 Nov 2019

Subscribe to our newsletter